Lung Non-Small Cell Carcinoma

In this phase 3, open-label, randomized trial, 452 patients with EGFR mutation-positive non-small cell lung cancer including exon 19 deletions and exon 21 L858R point mutations were randomized into co… (full text at CIViC)

PMID 28958502 · Wu et al., 2017 · Open in CIViC

In this phase 3, open-label, randomized trial, 452 patients with EGFR mutation-positive non-small cell lung cancer including exon 19 deletions and exon 21 L858R point mutations were randomized into co… (full text at CIViC)

PMID 28958502 · Wu et al., 2017 · Open in CIViC

The phase 3 (EURTAC) study consisted of of 173 non-small cell lung cancer patients who had not had prior chemotherapy for metastatic disease (although adjuvant or neoadjuvant chemotherapy was permitte… (full text at CIViC)

PMID 22285168 · Rosell et al., 2012 · Open in CIViC

In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplication… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In this phase 3, randomized, double-blind, placebo-controlled trial, 449 patients stage IV NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations. Patients were randomly assigned in a 1:1 rati… (full text at CIViC)

PMID 31591063 · Nakagawa et al., 2019 · Open in CIViC

In this phase-IV, open-label, single-arm study, 106 patients with NSCLC and EGFR mutations including exon 19 deletion and exon 21 L858R point mutations were administered 250 mg daily doses of gefitini… (full text at CIViC)

PMID 24263064 · Douillard et al., 2014 · Open in CIViC

A phase 2 study of 120 stage IIIB-IV lung adenocarcinoma patients reported improved progression free survival in patients with EGFR mutation (defined as exon 19 deletion or exon 21 mutation) when trea… (full text at CIViC)

PMID 24755888 · Yu et al., 2014 · Open in CIViC

In this phase 3, double-blind trial, 682 patients were randomly assigned 1:1 to either osimertinib (80 mg once daily) or placebo for 3 years following complete resection of EGFR mutation positive (exo… (full text at CIViC)

PMID 32955177 · Wu et al., 2020 · Open in CIViC

The phase 3 randomized LAURA trial (NCT NCT03521154) evaluated osimertinib as consolidation therapy after definitive chemoradiation in 216 patients with unresectable stage 3 non-small cell lung cancer… (full text at CIViC)

PMID 38828946 · Lu et al., 2024 · Open in CIViC

In this phase 3 clinical trial, 557 patients with NSCLC harbouring EGFR mutations (exon 19 deletion or L858R mutation) were randomly assigned to two groups and treated with either osimertinib with che… (full text at CIViC)

PMID 37937763 · Planchard et al., 2023 · Open in CIViC

Deguelin exhibits a potent inhibitory effect in gefitinib-resistant H1975 cells with EGFR L858R/T790M mutation. Decreased phosphorylation was noted in cell lines treated with deguelin but not gefitini… (full text at CIViC)

PMID 32081857 · Gao et al., 2020 · Open in CIViC

EGFR L861 mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a study of patients treated with erlotini… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplication… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a patient with metastatic adenocarcinoma of the lung harboring EGFR L861R mutation, MET D1028H and EGFR amplification, EGFR L861R was associated with acquired resistance to crizotinib monotherapy. … (full text at CIViC)

PMID 26845121 · Benderra et al., 2016 · Open in CIViC

In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L861R mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR M766_A767insAI demonstrated reduced sensitivity to erlotinib treatment (IC50=3.403�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

A 43 year old female neversmoker lung adenocarcinoma patient with EGFR M766_A767insASV mutation was given erlotinib as first line treatment, and had progressive disease as best response with -3.9% cha… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

L858R and L858R/M766Q mutations were retrovirally introduced into Ba/F3 and NIH/3T3 cells and evaluated for sensitivity to various EGFR inhibitors. Modeling suggested that EGFR M766Q could disrupt osi… (full text at CIViC)

PMID 31254668 · Castellano et al., 2019 · Open in CIViC

A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer. Sequencing of circulating cell-free DNA showed EGFR L858R, an acqui… (full text at CIViC)

PMID 31254668 · Castellano et al., 2019 · Open in CIViC

A 65-year-old female with lung adenocarcinoma underwent NGS testing, revealing an EGFR-MACF1 fusion at the RNA level (mutation abundance: 17%) and EGFR amplification (copy number: 24.15). The fusion i… (full text at CIViC)

PMID 38595815 · Wang et al., 2024 · Open in CIViC

In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001).

PMID 22810899 · Johnson et al., 2013 · Open in CIViC

Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease … (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC

This phase 1b/2, multicentre, randomized clinical trial was conducted on the combination of tepotinib and gefitinib on patients with MET overexpression or MET amplification that showed resistance to E… (full text at CIViC)

PMID 32479794 · Wu et al., 2020 · Open in CIViC

A transposon mutagenesis screen for resistance to a second-generation TKI afatinib was performed in EGFR-TKI sensitive PC9 lung adenocarcinoma cell line that harbours exon 19 EGFR deletion. YES1 was f… (full text at CIViC)

PMID 29875142 · Fan et al., 2018 · Open in CIViC

In an in vitro study, MCF-7 cells expressing the EGFR N771delinsGY (N771GY) mutation demonstrated sensitivity to dacomitinib (PF00299804), with YFP-EGFR-ICD relocation observed at 50 nM. In comparison… (full text at CIViC)

PMID 21132006 · Harada et al., 2011 · Open in CIViC

In a stage III lung adenocarcinoma patient of African-American descent with EGFR N771>GY mutation, EGFR N771>GY was reported to be resistant to erlotinib treatment. The patient was treated with 4 cycl… (full text at CIViC)

PMID 21132006 · Harada et al., 2011 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR N771insVH mutation was associated with resistance to erlotinib treatment. The patient survived… (full text at CIViC)

PMID 27032107 · De Grève et al., 2016 · Open in CIViC

In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 69 year old male with the novel EGFR exon 20 insertion N771_P772insL received osimertinib as first-line… (full text at CIViC)

PMID 31208370 · Fang et al., 2019 · Open in CIViC